Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Total Debt (2021 - 2026)

Axsome Therapeutics' Total Debt history spans 6 years, with the latest figure at $129.0 million for Q1 2026.

  • On a quarterly basis, Total Debt fell 32.1% to $129.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $129.0 million, a 32.1% decrease, with the full-year FY2025 number at $127.8 million, down 29.3% from a year prior.
  • Total Debt hit $129.0 million in Q1 2026 for Axsome Therapeutics, up from $127.8 million in the prior quarter.
  • Over the last five years, Total Debt for AXSM hit a ceiling of $190.0 million in Q1 2025 and a floor of $49.3 million in Q1 2022.
  • Historically, Total Debt has averaged $150.4 million across 5 years, with a median of $180.7 million in 2024.
  • Biggest five-year swings in Total Debt: soared 211.51% in 2023 and later tumbled 32.32% in 2025.
  • Tracing AXSM's Total Debt over 5 years: stood at $100.2 million in 2022, then soared by 84.18% to $184.5 million in 2023, then dropped by 2.04% to $180.7 million in 2024, then decreased by 29.3% to $127.8 million in 2025, then rose by 0.97% to $129.0 million in 2026.
  • Business Quant data shows Total Debt for AXSM at $129.0 million in Q1 2026, $127.8 million in Q4 2025, and $127.3 million in Q3 2025.